Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941446 | 0.92 | TACR2 (0.40) | TACR2TACR1KMT2ATACR3 | |
| SCHEMBL4630770 | 0.88 | KMT2A (0.41) | TACR2TACR1KMT2A | |
| SCHEMBL6665548 | 0.87 | KMT2A (0.40) | TACR2TACR1KMT2A | |
| SCHEMBL6666806 | 0.86 | TACR2 (0.40) | TACR2TACR1KMT2A | |
| SCHEMBL4631761 | 0.86 | TACR2 (0.49) | TACR2TACR1TACR3 | |
| SCHEMBL6661500 | 0.85 | KMT2A (0.38) | TACR2TACR1KMT2A | |
| SCHEMBL4940368 | 0.81 | KMT2A (0.40) | TACR2TACR1CNR2KMT2ATACR3 | |
| SCHEMBL4941690 | 0.76 | KDM4E (0.44) | TACR2KMT2A | |
| SCHEMBL6192006 | 0.75 | KMT2A (0.41) | TACR2TACR1CNR2KMT2ATACR3 | |
| SCHEMBL4630697 | 0.74 | TACR2 (0.50) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TACR2, TACR1, KIT | TACR2 1/4885TACR1 2/4885CNR2 28/4885 |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | KIT, TACR2, P2RX3 | TACR2 2/4885TACR1 4/4885CNR2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.